Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 63
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Gastroenterol Hepatol ; 39(9): 590-596, 2016 Nov.
Artículo en Español | MEDLINE | ID: mdl-27112800

RESUMEN

INTRODUCTION: Variceal upper gastrointestinal bleeding (UGIB) can trigger acute hypoxic hepatitis (AHH). The aim of this study was to analyse the incidence, associated risk factors and mortality of AHH after variceal UGIB. PATIENTS AND METHODS: Retrospective study of cirrhotic patients with variceal UGIB, classified into 2 groups according to the development of AHH. AHH was diagnosed when AST and ALT reached levels 10 times above the upper limit of normal, after ruling out other causes of hepatitis. The standard initial treatment consisted of haemodynamic support, emergency endoscopy with rubber band ligation, somatostatin and antibiotics. In the case of failure of primary haemostasis, a transjugular intrahepatic portosystemic shunt (TIPS) was implanted. Both groups (AHH and non-AHH) were compared. RESULTS: Sixty-eight cirrhotic patients with variceal UGIB admitted to the gastroenterology department of Hospital Ramón y Cajal between January 2007 and March 2012 were analysed. Eleven of these patients (16.2%) developed AHH. Univariate analysis showed the following items as risk factors: diabetes (OR: 7.5; CI: 1.9-29), shock (OR: 8.5; CI: 2.06-34) and persistent bleeding (OR: 9.0, CI: 1.6-49, P=.03). However, multivariate analysis confirmed only diabetes (OR: 8.61; CI: 1.4-52.5) and shock (OR: 7.58; CI: 1.26-45.51) as risk factors. Mortality rate in the AHH group was 45%, compared to 10.5% in the non-HAA group (P=.012). CONCLUSIONS: AHH after variceal UGIB occurred in 16.2% of cirrhotic patients and was associated with a poorer prognosis, with a mortality rate of 45%. Our findings suggest that diabetes and shock are risk factors for the development of AHH. Early identification of at-risk patients could therefore help prevent AHH.


Asunto(s)
Várices Esofágicas y Gástricas/complicaciones , Hemorragia Gastrointestinal/complicaciones , Isquemia/etiología , Hígado/irrigación sanguínea , Adulto , Anciano , Carcinoma Hepatocelular/epidemiología , Comorbilidad , Complicaciones de la Diabetes/epidemiología , Femenino , Humanos , Isquemia/mortalidad , Hepatopatías Alcohólicas/epidemiología , Neoplasias Hepáticas/epidemiología , Masculino , Persona de Mediana Edad , Vena Porta , Recurrencia , Estudios Retrospectivos , Factores de Riesgo , Trombosis/epidemiología
2.
Gastroenterol Hepatol ; 38(5): 305-12, 2015 May.
Artículo en Español | MEDLINE | ID: mdl-25636371

RESUMEN

BACKGROUND: Treatment of HBeAg-negative chronic hepatitis B (CHB) with nucleos(t)ide analogues (NA) is usually indefinite, since the loss of HBsAg, as a criterion for its discontinuation, is a rare event. Recent evidence suggests that discontinuing NA therapy may be feasible in selected patients. OBJECTIVES: To analyze the rate of virological relapse in patients with HBeAg-negative CHB who discontinued treatment with NAs. METHODS: We performed a single-center observational study that included 140 patients with HBsAg-negative CHB. Twenty-two patients, who received only NAs, discontinued treatment for different reasons and were subsequently monitored. All had normal ALT and AST, undetectable DNA and absence of cirrhosis or significant comorbidities before stopping treatment. RESULTS: Twelve patients showed virologic relapse (54.54%). The mean interval between discontinuation and relapse was 6.38 months (± 1.9) (75% relapsed during the first 12 months after discontinuation). Five received adefovir, 1 lamivudine and adefovir, 1 tenofovir and 5 lamivudine alone. The mean treatment duration in this group was 38.5 months (± 4.5). The sustained response group had a higher mean age and longer treatment duration than patients with virologic relapse but these differences were not statistically significant. CONCLUSIONS: The results suggest that NA treatment can be stopped in selected patients with CHB as long as they are not cirrhotic, have completed a minimum period of treatment, have normal ALT and sustained undetectable DNA. These patients should be closely monitored during the first year and then indefinitely.


Asunto(s)
Alanina Transaminasa/sangre , Antivirales/uso terapéutico , Antígenos e de la Hepatitis B/inmunología , Hepatitis B Crónica/tratamiento farmacológico , Nucleótidos/uso terapéutico , Adulto , Anciano , Aspartato Aminotransferasas/sangre , ADN Viral/aislamiento & purificación , Quimioterapia Combinada , Femenino , Virus de la Hepatitis B/genética , Virus de la Hepatitis B/inmunología , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/inmunología , Humanos , Cirrosis Hepática/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Recurrencia , Resultado del Tratamiento
3.
Acta Gastroenterol Latinoam ; 45(3): 230-2, 2015 09.
Artículo en Español | MEDLINE | ID: mdl-28590608

RESUMEN

Syphilis is a chronic systemic infection mainly transmitted through sexual contact that shows a great variety of clinical manifestations. Liver involvement is an unusual complication mainly reported in HIV patients. In this case report we present a case of a 42-year-old immunocompent man with acute cholestatic hepatitis who was finally diagnosed of luetic hepatitis. Liver disease was the only manifestation of syphilis infection difficulty it's diagnostic. We emphasize the importance of including syphilis in the differential diagnosis of abnormal liver function tests in patients at risk of sexually transmitted diseases due to its resolution with appropriate antibiotic treatment.


Asunto(s)
Hepatitis/microbiología , Sífilis/complicaciones , Enfermedad Aguda , Adulto , Hepatitis/diagnóstico , Humanos , Inmunocompetencia , Masculino , Sífilis/diagnóstico
4.
Gastroenterol Hepatol ; 37(5): 280-8, 2014 May.
Artículo en Español | MEDLINE | ID: mdl-24462611

RESUMEN

INTRODUCTION: Due to globalization and migratory movements, HBeAg+ chronic hepatitis B is becoming increasingly important in Spain. OBJECTIVE: To analyze the epidemiological features, progression, and treatment response to oral antiviral agents (OA) in HBeAg+ chronic hepatitis B patients in our area. MATERIAL AND METHODS: We analyzed 436 patients with chronic hepatitis B infection followed up at the Ramón y Cajal Hospital from 1990 to June 2012. RESULTS: Sixty-five patients (14.9%) had HBeAg+ chronic hepatitis B. Seven patients in the immunotolerant phase were not treated, while the remaining 58 received treatment. Four patients were excluded: two due to severe acute hepatitis, one due to hepatitis C virus coinfection and another because of a Delta virus coinfection. Of the remaining 54 patients, 19 received interferon with or without OA, and 35 received only OA. Two patients treated for less than 1 month were not included in the analysis. The analysis was finally performed in 33 patients. The mean duration of treatment was 46.81 months (6-138). Lamivudine was the most frequently prescribed drug (39.39%) followed by tenofovir (24.24%) and entecavir (21.21%). The mean age was 42.08±14 years and 75.75% (25/33) of the patients were male. Nineteen of 33 patients (57.57%) achieved seroconversion to anti-HBe, and 27.27% (9/33) showed clearance of HBsAg. There was no evidence of HBsAg reversion after a mean follow-up of 35.6 months. There were 8 cases of resistance in 7 patients: 7 to lamivudine and 1 to adefovir. CONCLUSIONS: Approximately 15% of chronic hepatitis B patients in our area are HBeAg+. Treatment with OA achieves a high seroconversion rate (57.57%) and a considerable percentage of HBsAg clearance (27.27%).


Asunto(s)
Antivirales/administración & dosificación , Hepatitis B Crónica/tratamiento farmacológico , Administración Oral , Adulto , Anciano , Femenino , Antígenos e de la Hepatitis B/sangre , Hepatitis B Crónica/sangre , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
5.
Gastroenterol Hepatol ; 36(4): 274-9, 2013 Apr.
Artículo en Español | MEDLINE | ID: mdl-23522394

RESUMEN

Acute hypertriglyceridemic pancreatitis is the third cause of acute pancreatitis in the Western population. There is usually an underlying alteration in lipid metabolism and a secondary factor. Clinical presentation is similar to that of pancreatitis of other etiologies, but the course of acute hypertriglyceridemic pancreatitis seems to be worse and more recurrent. Some laboratory data can be artefacts, leading to diagnostic errors. This is the case of amylase, which can show false low levels. Treatment is based on intense fluidotherapy and analgesia. When there is no response to conservative management, other methods to lower triglyceride levels should be used. Several options are available, such as plasmapheresis, insulin, and heparin. The present article provides a review of the current literature on this entity.


Asunto(s)
Hipertrigliceridemia/complicaciones , Pancreatitis/etiología , Dolor Abdominal/etiología , Enfermedad Aguda , Alcoholismo/complicaciones , Amilasas/sangre , Complicaciones de la Diabetes , Errores Diagnósticos , Susceptibilidad a Enfermedades , Reacciones Falso Negativas , Femenino , Fluidoterapia , Alimentos Formulados , Heparina/uso terapéutico , Humanos , Hiperlipoproteinemia Tipo IV/complicaciones , Hipertrigliceridemia/sangre , Hipertrigliceridemia/terapia , Insulina/uso terapéutico , Lipoproteínas LDL/sangre , Náusea/etiología , Obesidad/complicaciones , Pancreatitis/diagnóstico , Pancreatitis/terapia , Plasmaféresis , Embarazo , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/terapia , Sodio/sangre
6.
Gastroenterol Hepatol ; 35(8): 567-71, 2012 Oct.
Artículo en Español | MEDLINE | ID: mdl-22608492

RESUMEN

Chylous ascites is infequent after abdominal surgery. We describe the case of a 43-year-old man with portal cavernomatosis who underwent surgery to insert a splenorenal shunt, which was not placed due to the absence of signs of portal hypertension. On postoperative day 20, the patient developed abdominal distension and mild dyspnea and was diagnosed with chylous ascites, which was related to the surgery. The patient was initially treated with diet and diuretics, with no clinical response, and consequently octreotide therapy was started. Four days later, the ascites was almost resolved and an ultrasound scan at 4 months showed its complete disappearance. This article demonstrates the effectiveness of octreotide in the treatment of postsurgical chylous ascites.


Asunto(s)
Ascitis Quilosa/tratamiento farmacológico , Octreótido/uso terapéutico , Complicaciones Posoperatorias/tratamiento farmacológico , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Anticoagulantes/uso terapéutico , Ascitis Quilosa/diagnóstico por imagen , Ascitis Quilosa/dietoterapia , Ascitis Quilosa/etiología , Circulación Colateral , Terapia Combinada , Diuréticos/uso terapéutico , Várices Esofágicas y Gástricas/etiología , Várices Esofágicas y Gástricas/cirugía , Humanos , Hipertensión Portal/complicaciones , Hipertensión Portal/etiología , Hipertensión Portal/cirugía , Ligadura , Masculino , Venas Mesentéricas/cirugía , Vena Porta/anomalías , Vena Porta/cirugía , Complicaciones Posoperatorias/diagnóstico por imagen , Complicaciones Posoperatorias/dietoterapia , Complicaciones Posoperatorias/etiología , Adherencias Tisulares/complicaciones , Ultrasonografía , Trombosis de la Vena/etiología , Trombosis de la Vena/cirugía
7.
Gastroenterol Hepatol ; 35(10): 697-9, 2012 Dec.
Artículo en Español | MEDLINE | ID: mdl-22749503

RESUMEN

There are multiple causes of hepatitis. The most frequent etiologies are viral, usually hepatitis A, B and C viruses. However, other, non-hepatotropic viruses can cause this disease, including parvovirus B19. We present a case of acute hepatitis due to parvovirus B19, as well as a review of the epidemiological, clinical, diagnostic and therapeutic features of this entity.


Asunto(s)
Hepatitis Viral Humana/virología , Infecciones por Parvoviridae/virología , Parvovirus B19 Humano/patogenicidad , Enfermedad Aguda , Adulto , Anticuerpos Antivirales/sangre , ADN Viral/análisis , Diagnóstico Diferencial , Hepatitis Viral Humana/epidemiología , Humanos , Masculino , Infecciones por Parvoviridae/diagnóstico , Infecciones por Parvoviridae/epidemiología , Parvovirus B19 Humano/genética , Parvovirus B19 Humano/inmunología , Parvovirus B19 Humano/aislamiento & purificación
9.
Gastroenterol Hepatol ; 34(6): 398-400, 2011.
Artículo en Español | MEDLINE | ID: mdl-21571397

RESUMEN

Hepatitis E virus (HEV) is a Herpesvirus, with four different genotypes. Genotypes 1 and 2 often cause acute hepatitis, which presents as outbreaks in endemic regions of Asia and Africa. Genotypes 3 and 4 cause sporadic cases of acute hepatitis in Europe and North America, where it is considered a zoonosis. Symptoms usually resolve spontaneously, but in recent years cases have been detected that progress to chronic liver disease mainly in immunocompromised patients (patients with solid organ transplants, lymphoma, human immunodeficiency virus, primary immunodeficiencies, and those under treatment with corticosteroids and immunosuppressive agents..). We report the case of a healthy, immunocompetent man who developed an episode of acute HEV hepatitis, which progressed to chronic liver disease with fibrosis grade III/IV in the liver biopsy within a year and half.


Asunto(s)
Hepatitis E/diagnóstico , Anciano , Enfermedad Crónica , Humanos , Inmunocompetencia , Masculino
14.
Gastroenterol Hepatol ; 32(10): 687-92, 2009 Dec.
Artículo en Español | MEDLINE | ID: mdl-19732994

RESUMEN

Anticonvulsant hypersensitivity syndrome is an unpredictable, potentially fatal drug reaction to aromatic anticonvulsants such as carbamazepine, phenytoin and phenobarbital. The hallmark features include fever, eosinophilia, rash and involvement of one or more internal organs. Clearly established diagnostic criteria and treatment guidelines are lacking. A high index of suspicion is required to identify this syndrome, allowing early withdrawal of the drug and avoiding re-exposure. We report an illustrative case of anticonvulsant hypersensitivity syndrome and review the published literature.


Asunto(s)
Anemia Hemolítica/inducido químicamente , Anticonvulsivantes/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Erupciones por Medicamentos/etiología , Epilepsia Parcial Compleja/tratamiento farmacológico , Epilepsia del Lóbulo Temporal/tratamiento farmacológico , Enfermedades Linfáticas/inducido químicamente , Fenitoína/efectos adversos , Adolescente , Aminas/uso terapéutico , Anticonvulsivantes/uso terapéutico , Astrocitoma/complicaciones , Astrocitoma/diagnóstico , Astrocitoma/cirugía , Neoplasias Encefálicas/complicaciones , Neoplasias Encefálicas/cirugía , Carbamazepina/administración & dosificación , Carbamazepina/uso terapéutico , Ácidos Ciclohexanocarboxílicos/uso terapéutico , Errores Diagnósticos , Quimioterapia Combinada , Epilepsia Parcial Compleja/etiología , Epilepsia del Lóbulo Temporal/etiología , Femenino , Gabapentina , Ganglioneuroma/diagnóstico , Humanos , Giro Parahipocampal/cirugía , Fenitoína/administración & dosificación , Fenitoína/uso terapéutico , Radiocirugia , Ácido gamma-Aminobutírico/uso terapéutico
15.
Gastroenterol Hepatol ; 31(2): 98-103, 2008 Feb.
Artículo en Español | MEDLINE | ID: mdl-18279648

RESUMEN

Epiploic appendages are fat-filled, serosa-covered pediculated formations originating in the external wall of the bowel, toward the peritoneal cavity. Torsion of the epiploic appendages produces strangulation and infarction of the pedicle, initially venous and, when prolonged, ischemic, resulting in epiploic appendagitis. The main clinical manifestation is abdominal pain. Diagnosis is established through imaging techniques (ultrasound and computed tomography). Treatment is conservative and the prognosis is excellent.


Asunto(s)
Apendicitis/diagnóstico , Enfermedades del Colon , Anomalía Torsional , Dolor Abdominal/etiología , Analgésicos/uso terapéutico , Antibacterianos , Calcinosis/etiología , Colon/irrigación sanguínea , Colon/diagnóstico por imagen , Enfermedades del Colon/complicaciones , Enfermedades del Colon/diagnóstico , Enfermedades del Colon/fisiopatología , Enfermedades del Colon/terapia , Contraindicaciones , Diagnóstico Diferencial , Hemoperitoneo/etiología , Humanos , Infarto/etiología , Obesidad/complicaciones , Tomografía Computarizada por Rayos X , Anomalía Torsional/complicaciones , Anomalía Torsional/diagnóstico , Anomalía Torsional/fisiopatología , Anomalía Torsional/terapia , Pérdida de Peso
17.
Gastroenterol Hepatol ; 30(4): 244-50, 2007 Apr.
Artículo en Español | MEDLINE | ID: mdl-17408555

RESUMEN

Chronic abdominal pain is a common clinical problem in primary care, and is usually referred to gastroenterologists or general surgeons. Although up to 20% of cases of idiopathic abdominal pain arise in structures of the abdominal wall, this is frequently overlooked as a possible cause. It includes pain arising from structures of the abdominal wall including skin, parietal peritoneum, cellular subcutaneous tissue, aponeuroses, abdominal muscles and somatosensorial innervation from lower dorsal roots. The diagnosis is based on anamnesis and physical examination. Carnett's sign is a simple maneuver that discriminates between parietal and visceral pain. Management with topical anesthesia is effective in a majority of patients and can help to confirm the diagnosis.


Asunto(s)
Dolor Abdominal/etiología , Pared Abdominal/fisiopatología , Dolor Abdominal/diagnóstico , Dolor Abdominal/epidemiología , Dolor Abdominal/fisiopatología , Dolor Abdominal/terapia , Pared Abdominal/inervación , Anestésicos Locales/administración & dosificación , Anestésicos Locales/uso terapéutico , Enfermedad Crónica , Hematoma/diagnóstico , Hematoma/fisiopatología , Hernia Abdominal/diagnóstico , Humanos , Inyecciones , Contracción Muscular , Síndromes del Dolor Miofascial/diagnóstico , Síndromes de Compresión Nerviosa/diagnóstico , Síndromes de Compresión Nerviosa/fisiopatología , Fibras Nerviosas Mielínicas/fisiología , Fibras Nerviosas Amielínicas/fisiología , Nociceptores/fisiología , Fenol/administración & dosificación , Fenol/uso terapéutico , Examen Físico , Piel/inervación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA